BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34167431)

  • 1. Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes.
    Richardson E; García-Bernal D; Calabretta E; Jara R; Palomo M; Baron RM; Yanik G; Fareed J; Vlodavsky I; Iacobelli M; Díaz-Ricart M; Richardson PG; Carlo-Stella C; Moraleda JM
    Expert Opin Ther Targets; 2021 Jun; 25(6):423-433. PubMed ID: 34167431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.
    Mo CC; Richardson E; Calabretta E; Corrado F; Kocoglu MH; Baron RM; Connors JM; Iacobelli M; Wei LJ; Rapoport AP; Díaz-Ricart M; Moraleda JM; Carlo-Stella C; Richardson PG
    Blood Rev; 2024 Jul; 66():101218. PubMed ID: 38852017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Maccio et al, "Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?".
    Richardson E; Carlo-Stella C; Jara R; Vlodavsky I; Iacobelli M; Fareed J; Mo C; O'Gorman P; Yanik G; Palomo M; Diaz-Ricart M; Moraleda JM;
    J Thromb Haemost; 2020 Nov; 18(11):3111-3113. PubMed ID: 32860297
    [No Abstract]   [Full Text] [Related]  

  • 4. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells.
    Falanga A; Vignoli A; Marchetti M; Barbui T
    Leukemia; 2003 Aug; 17(8):1636-42. PubMed ID: 12886253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo.
    Koehl GE; Geissler EK; Iacobelli M; Frei C; Burger V; Haffner S; Holler E; Andreesen R; Schlitt HJ; Eissner G
    Cancer Biol Ther; 2007 May; 6(5):686-90. PubMed ID: 17495522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19.
    Wang X; Sahu KK; Cerny J
    J Thromb Thrombolysis; 2021 Apr; 51(3):657-662. PubMed ID: 33063256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications.
    Nägele MP; Haubner B; Tanner FC; Ruschitzka F; Flammer AJ
    Atherosclerosis; 2020 Dec; 314():58-62. PubMed ID: 33161318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defibrotide for the Treatment of Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2 Pediatric Patients.
    Lang P; Eichholz T; Bakchoul T; Streiter M; Petrasch M; Bösmüller H; Klein R; Rabsteyn A; Lang AM; Adams C; Klingel K; Gessner M; Rosenberger P; Ruef P; Handgretinger R
    J Pediatric Infect Dis Soc; 2020 Nov; 9(5):622-625. PubMed ID: 32951037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Graft-vs.-Host Disease-Associated Endothelial Activation
    Martinez-Sanchez J; Hamelmann H; Palomo M; Mir E; Moreno-Castaño AB; Torramade S; Rovira M; Escolar G; Cordes S; Kalupa M; Mertlitz S; Riesner K; Carreras E; Penack O; Diaz-Ricart M
    Front Immunol; 2019; 10():2339. PubMed ID: 31649666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?
    Macciò A; Madeddu C; Caocci G; La Nasa G
    J Thromb Haemost; 2020 Nov; 18(11):3106-3108. PubMed ID: 32692894
    [No Abstract]   [Full Text] [Related]  

  • 11. Progressive endothelial cell damage in correlation with sepsis severity. Defibrotide as a contender.
    Fernández S; Palomo M; Molina P; Díaz-Ricart M; Escolar G; Téllez A; Seguí F; Ventosa H; Torramade-Moix S; Rovira M; Carreras E; Nicolás JM; Castro P
    J Thromb Haemost; 2021 Aug; 19(8):1948-1958. PubMed ID: 33872468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
    Ulutin ON; Cizmeci G; Balkuv-Ulutin S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae.
    Richardson PG; Palomo M; Kernan NA; Hildebrandt GC; Chao N; Carreras E
    Bone Marrow Transplant; 2021 Dec; 56(12):2889-2896. PubMed ID: 34584241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome.
    Spiropoulou CF; Srikiatkhachorn A
    Virulence; 2013 Aug; 4(6):525-36. PubMed ID: 23841977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defibrotide in the COVID-19 coagulopathy: What is the timing?
    Macciò A; Madeddu C; Caocci G; Oppi S; La Nasa G
    J Thromb Haemost; 2020 Nov; 18(11):3113-3115. PubMed ID: 32945111
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19.
    Perico L; Benigni A; Casiraghi F; Ng LFP; Renia L; Remuzzi G
    Nat Rev Nephrol; 2021 Jan; 17(1):46-64. PubMed ID: 33077917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.
    Higashikuni Y; Liu W; Obana T; Sata M
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defibrotide: properties and clinical use of an old/new drug.
    Pescador R; Capuzzi L; Mantovani M; Fulgenzi A; Ferrero ME
    Vascul Pharmacol; 2013; 59(1-2):1-10. PubMed ID: 23680861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial Dysfunction as a Primary Consequence of SARS-CoV-2 Infection.
    Mezoh G; Crowther NJ
    Adv Exp Med Biol; 2021; 1321():33-43. PubMed ID: 33656711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide.
    Carmona A; Díaz-Ricart M; Palomo M; Molina P; Pino M; Rovira M; Escolar G; Carreras E
    Biol Blood Marrow Transplant; 2013 Oct; 19(10):1439-45. PubMed ID: 23845694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.